+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06742125

Comparison of Drug-Coated Balloon Versus Drug-Eluting Stent Treatment in Patients with ST-Segment Elevation Myocardial Infarction

Led by Second Affiliated Hospital, Zhejiang University, School of Medicine · Updated on 2026-09-28

1244

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

ST-segment elevation myocardial infarction STEMI is a serious emergency that requires immediate treatment. Premature coronary artery disease is increasing rapidly in China, often leading to acute myocardial infarction with poor long-term outcomes. Current treatments like primary percutaneous coronary intervention PCI or coronary artery bypass grafting are high-risk and place heavy burdens on patients and families. Even with new drug-eluting stents, the risk of death or heart attack within 6 years remains significant, and managing stent failure is challenging. Drug-coated balloon DCB angioplasty offers a promising alternative, especially for younger patients, but more data are needed on its use in large-vessel disease and acute STEMI. This study compares clinical outcomes between drug-coated balloon and drug-eluting stent treatments in STEMI patients. It is an investigator-initiated, open-label, prospective, multicenter randomized clinical trial enrolling 1244 patients across multiple centers in China. Participants who have successfully undergone lesion pretreatment will be randomly assigned to either the DCB group or the DES group, with 622 patients in each arm. Both treatments involve percutaneous coronary intervention targeting the affected coronary artery lesions. Participants will be monitored for up to 60 months to assess outcomes including the incidence of patient-oriented composite endpoints POCE, target vessel failure, mortality, non-fatal myocardial infarction, and need for revascularization. Assessments will include direct measurements and coronary angiography at 12, 36, and 60 months. Safety, clinical events, and inflammatory markers will also be evaluated throughout the follow-up period. The primary outcome is the incidence of POCE at 12 months.

CONDITIONS

Brief Title

Drug-Coated Balloon Versus Drug-Eluting Stent in Patient With ST-Segment Elevation Myocardial Infarction

Research Team

J

Jucheng Zhang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here